Spero Therapeutics, Inc.

NASDAQ:SPRO

Biotechnology

Healthcare
$0.87 +3.79%

+$0.08 today

Market cap
$50.92M
Beta
1.46
P/E (TTM)
8.2
EPS (TTM)
$0.27
52W Low $1.80High $3.22

Volume 0.27M

Average 0.78M

Returns on capital

Spero Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

14.5%

avg -539.8%

ROIC

-0.0%

avg -242.8%

ROA

12.4%

avg -58.5%

Analysis

ROE is currently the strongest return metric at 14.5% versus its period average of -539.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Esther Rajavelu

CEO, President, CFO, Chief Business Officer, Treasurer & DirectorUSD 1.65M47946.00K1.63%

Timothy Keutzer

Chief Operating OfficerUSD 1.23M58742.51K1.28%

Amy Dix Rock

Chief Regulatory & Quality Officer—55——

Dae Gon Ha

Senior Vice President of Corporate Development————

John Raymond

Senior Vice President of Finance & Business Operations————

Debra Jeske Zack

Chief Medical Officer—69——

Sheila Finan

Senior VP & Controller————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 9, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

9

$499,087.28

Net Transaction Value

−$499,087.28

Net selling

Most Active

Rajavelu Esther

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 9, 26

Rajavelu Esther

Direct

Sell$42.5K
May 4, 26

Rajavelu Esther

Direct

Sell$63.4K
Feb 6, 26

Rajavelu Esther

Direct

Sell$87.6K
Feb 6, 26

Rajavelu Esther

Direct

Sell$119.9K
Feb 6, 26

Keutzer Timothy

Direct

Sell$44K
Feb 4, 26

Keutzer Timothy

Direct

Sell$7.8K
Feb 3, 26

Keutzer Timothy

Direct

Sell$51.8K
Feb 2, 26

Keutzer Timothy

Direct

Sell$41.6K
Feb 2, 26

Rajavelu Esther

Direct

Sell$40.6K

Summary

Insiders reported 0 buys worth $0.00 and 9 sells worth $499,087.28 over the last 12 months. That adds up to net selling of $499,087.28. Rajavelu Esther was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+7.1%
-31.8% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +7.1% over three years. Forward estimates point to Revenue at -31.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Spero Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SPRO's management, answered from reported figures.

Who manages SPRO?

Spero Therapeutics, Inc. (SPRO) lists 7 active executives. The top listed executive is Amy Dix Rock, Chief Regulatory & Quality Officer.

Are SPRO insiders buying or selling?

Recent insider activity shows net buying of $32.02M.